Document is current
Any future updates will be listed below
-
Authors
Kuo, Grace
Kumbhar, Ramhari
Blair, William
Dawson, Valina L.
Dawson, Ted M.
Mao, Xiaobo https://orcid.org/0000-0001-6587-556X
-
Funding
Funding for this research was provided by:
National Institute on Aging (R01AG073291, R01AG071820, RF1AG079487, K01AG056841, P50 AG05146, R01 AG085688, R01AG089605)
CurePSP (658-2018-06)
AFAR New Investigator Award in Alzheimer’s disease (AFAR New Investigator Award in Alzheimer’s disease)
National Institute of Neurological Disorders and Stroke (R01NS107318, RF1NS125592, R21NS125559, RF1NS137428)
Parkinson’s Foundation (PF-JFA-1933)
Maryland Stem Cell Research Foundation (2019-MSCRFD-4292)
American Parkinson Disease Association (American Parkinson Disease Association)
JPB Foundation (JPB Foundation)
Aligning Science Across Parkinson’s (Aligning Science Across Parkinson’s)
Farmer Family Foundation Parkinson’s Research Initiative (Farmer Family Foundation Parkinson’s Research Initiative, Farmer Family Foundation Parkinson’s Research Initiative)
- License Information
-
More Information
Article History
Received: 11 July 2024
Accepted: 5 January 2025
First Online: 23 January 2025
Declarations
:
: Not applicable.
: Not applicable.
: T.M.D., V.L.D. and X.B.M. has filed a patent for therapeutic uses of Lag3 (application No: PCT/US2017/047878). X.B.M. and R.K. has a patent filed for use of nanobody PFF-NB2 to treat α-synucleinopathies (application no: PCT/US2022/037038). XBM has a patent filed for use of nanozymes for treating neurodegenerative diseases (application no: PCT/US2023/078741, PCT/US2021/059530). All other authors declare no conflicts of interest.
